Biocompatibility assessment of peritoneal dialysis solutions with a new in vitro model of preconditioned human HL60 cells

Artificial Organs

Volumn 33, Issue 7, 2009, Pages 544-550

  Koball, Sebastian ^a   Korten, Gero ^a   Stange, Jan ^a   Schmidt, Reinhard ^a   Mitzner, Steffen ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Biocompatibility testing; HL60 cells; Neutrophils; Peritoneal dialysis

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BIOCOMPATIBILITY; CELL CULTURE; CELLS; CHEMILUMINESCENCE; DIALYSIS; TESTING;

BIOCOMPATIBILITY TESTING; CELL-BE; CELL/B.E; CELL/BE; GLUCOSE CONCENTRATION; HL-60 CELLS; HUMAN HL-60 CELL; IN-VITRO MODELS; NEUTROPHILE; PERITONEAL DIALYSIS;

GLUCOSE;

AMINO ACID; DIALYSIS FLUID; GLUCOSE; ICODEXTRIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID;

ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL STRAIN HL 60; CELL VIABILITY; CHEMOLUMINESCENCE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOTOXICITY; DONOR; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKOCYTE; MODEL; NEUTROPHIL; PERITONEAL DIALYSIS; PERITONEUM; PH; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS;

EID: 67650835393     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2009.00735.x     Document Type: Article

References (49)

1. Brauner A, Hylander B, Jacobson SH, Moshfegh A, Lundahl J. Increased expression of CD25 and HLA-DR on lymphocytes recruited into the peritoneal cavity in non-infected CAPD patients. Inflammation 2001 25 : 399 404. (Pubitemid 33139700)
2. Jorres A, Gahl GM. Effect of peritoneal dialysis fluids on leukocyte function. Perit Dial Int 1994 14 (Suppl 3 S29 32.
3. Alobaidi HM, Coles GA, Davies M, Lloyd D. Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function. Nephrol Dial Transplant 1986 1 : 16 21. (Pubitemid 18003290)
4. Betjes MG, Tuk CW, Visser CE, et al. Analysis of the peritoneal cellular immune system during CAPD shortly before a clinical peritonitis. Nephrol Dial Transplant 1994 9 : 684 92.
5. Holmes CJ. Peritoneal host defense mechanisms. Perit Dial Int 1996 16 (Suppl 1 S124 5.
6. Topley N, Kaur D, Petersen MM, et al. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996 7 : 218 24.
7. Lameire N, Van Biesen W, Van Landschoot M, et al. Experimental models in peritoneal dialysis: a European experience. Kidney Int 1998 54 : 2194 206.
8. Witowski J, Jorres A. Glucose degradation products: relationship with cell damage. Perit Dial Int 2000 20 (Suppl 2 S31 6.
9. Jorres A, Gahl GM, Ludat K, Frei U, Passlick-Deetjen J. In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 1997 12 : 543 9.
10. Brulez HF, Ter Wee PM, Snijders SV, Donker AJ, Verbrugh HA. Mononuclear leucocyte function tests in the assessment of the biocompatibility of peritoneal dialysis fluids. J Clin Pathol 1999 52 : 901 9.
11. Skoufos L, Topley N, Cooker L, et al. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid. Kidney Int Suppl 2003 88 : S94 9.
12. Ito T, Yorioka N, Yamamoto M, Kataoka K, Yamakido M. Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. J Am Soc Nephrol 2000 11 : 1969 79.
13. Yung S, Chan TM. Mesothelial cells. Perit Dial Int 2007 27 (Suppl 2 S110 15.
14. Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991 40 : 77 9.
15. Wang SY, Liu ST, Wang SJ, Ho CK. Induction of differentiation in HL-60 cells by retinoic acid and lymphocyte-derived differentiation-inducing factor but not by recombinant G-CSF and GM-CSF. Leuk Res 1989 13 : 1091 7.
16. Bunce CM, Mountford JC, French PJ, et al. Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochim Biophys Acta 1996 1311 : 189 98.
17. Gomez-Cambronero J, Frye T, Baumann M. Ribosomal p70S6K basal activity increases upon induction of differentiation of myelomonocytic leukemic cell lines HL60, AML14 and MPD. Leuk Res 2004 28 : 755 62.
18. Lill MC, Fuller JF, Herzig R, Crooks GM, Gasson JC. The role of the homeobox gene, HOX B7, in human myelomonocytic differentiation. Blood 1995 85 : 692 7.
19. Breborowicz A, Oreopoulos DG. In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Perit Dial Int 1996 16 (Suppl 1 S119 23.
20. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int 1995 15 : 158 64.
21. Schambye HT, Flesner P, Pedersen RB, et al. Bicarbonate- versus lactate-based CAPD fluids: a biocompatibility study in rabbits. Perit Dial Int 1992 12 : 281 6.
22. Schambye HT, Pedersen FB, Christensen HK, Berthelsen H, Wang P. The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate/lactate ratios. Perit Dial Int 1993 13 (Suppl 2 S116 8.
23. Coles GA, O'Donoghue DJ, Pritchard N, et al. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD - final report. Nephrol Dial Transplant 1998 13 : 3165 71.
24. Garcia-Lopez E, Lindholm B, Tranaeus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience. Perit Dial Int 2000 20 (Suppl 5 S48 56.
25. Ahmed N, Williams JF, Weidemann MJ. The human promyelocytic HL60 cell line: a model of myeloid cell differentiation using dimethylsulphoxide, phorbol ester and butyrate. Biochem Int 1991 23 : 591 602.
26. Chang HH, Oh PY, Ingber DE, Huang S. Multistable and multistep dynamics in neutrophil differentiation. BMC Cell Biol 2006 7 : 11.
27. Curran T, Bravo R, Muller R. Transient induction of c-fos and c-myc in an immediate consequence of growth factor stimulation. Cancer Surv 1985 4 : 655 81.
28. Fontana JA, Emler C, Ku K, McClung JK, Butcher FR, Durham JP. Cyclic AMP-dependent and -independent protein kinases and protein phosphorylation in human promyelocytic leukemia (HL60) cells induced to differentiate by retinoic acid. J Cell Physiol 1984 120 : 49 60. (Pubitemid 14083582)
29. Hughes PJ, Zhao Y, Chandraratna RA, Brown G. Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways. J Cell Biochem 2006 97 : 327 50.
30. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979 54 : 713 33.
31. Imaizumi M, Sato A, Koizumi Y, et al. Potentiated maturation with a high proliferating activity of acute promyelocytic leukemia induced in vitro by granulocyte or granulocyte/macrophage colony-stimulating factors in combination with all-trans retinoic acid. Leukemia 1994 8 : 1301 8.
32. Mitzner SR, Freytag J, Sauer M, et al. Use of human preconditioned phagocytes for extracorporeal immune support: introduction of a concept. Ther Apher 2001 5 : 423 32.
33. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980 77 : 2936 40.
34. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987 70 : 1233 44.
35. Mortier S, Faict D, Gericke M, Lameire N, De Vriese A. Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane. Nephron Exp Nephrol 2005 101 : e139 45.
36. Shockley TR, Martis L, Tranaeus AP. New solutions for peritoneal dialysis in adult and pediatric patients. Perit Dial Int 1999 19 (Suppl 2 S429 34.
37. Martis L, Chen C, Moberly JB. Peritoneal dialysis solutions for the 21st century. Artif Organs 1998 22 : 13 6.
38. Grzegorzewska AE. Protecting the peritoneal membrane in dialyzed patients. Adv Med Sci 2006 51 191 6.
39. Krediet RT, van Westrhenen R, Zweers MM, Struijk DG. Clinical advantages of new peritoneal dialysis solutions. Nephrol Dial Transplant 2002 17 (Suppl 3 16 8.
40. Chung SH, Stenvinkel P, Bergstrom J, Lindholm B. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 2000 20 (Suppl 5 S57 67.
41. Liberek T, Topley N, Jorres A, Coles GA, Gahl GM, Williams JD. Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. J Am Soc Nephrol 1993 3 : 1508 15.
42. Krediet RT, Zweers MM, van Westrhenen R, Ho-Dac-Pannekeet MM, Struijk DG. What can we do to preserve the peritoneum? Perit Dial Int 2003 23 (Suppl 2 S14 9.
43. Brulez HF, Dekker HA, Oe PL, Verbeelen D, ter Wee PM, Verbrugh HA. Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid. Nephron 1996 74 : 26 32. (Pubitemid 26300645)
44. Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial 2004 17 : 498 504. (Pubitemid 40110436)
45. Hiramatsu T, Furuta S, Kakuta H. Favorable changes in lipid metabolism and cardiovascular parameters after icodextrin use in peritoneal dialysis patients. Adv Perit Dial 2007 23 : 58 61.
46. Rodriguez-Carmona A, Perez FM, Garcia LE, Garcia FT, Diaz CH. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007 27 : 260 6.
47. Feriani M, Biasioli S, Chiaramonte S, et al. Will bicarbonate-CAPD strengthen the natural defence by having a physiological pH and a natural buffer? Contrib Nephrol 1987 57 : 101 9.
48. Plum J, Lordnejad MR, Grabensee B. Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998 54 : 224 35.
49. Rippe B, Simonsen O, Heimburger O, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001 59 : 348 57.